Oh dear, recycling cherry picked bits.In this bit you wrote...

Oh dear, recycling cherry picked bits.

In this bit you wrote

"Another question I have is why, if this is being widely used in Japan, have there been no publications on the successes of the treatment? There was one that was posted from I think 2021 that says it's still unclear if there's any benefit, and more trials are needed.

That's not a good sign. If haematologists were having great successes using a new experimental treatment, they should be clambering to write up the results and get some easy publications."

Based on the paper I found for you , just to refresh the memory, I looked after you wrote;

"It's absolutely bizarre.

For a "revolutionary" therapy that has been on the shelves in Japan for years now, there is absolutely no publications I can find on its use in last two years.

No trials, no case studies, no real data whatsoever.

This is mind boggling"

- But clearly did not look at all,

https://hotcopper.com.au/posts/67532487/single

Now for quibble at hand, around the bit I've quoted from you at the start, clearly I believe, referring to this bit, and recycling the same tired idea,



Which was from this post https://hotcopper.com.au/posts/67534533/single

How do you justify twisting and ignoring the context of the authors reference to ruxolitinib?